Prodrug design of phenolic drugs
Language English Country United Arab Emirates Media print
Document type Journal Article, Research Support, Non-U.S. Gov't, Review
PubMed
20443775
DOI
10.2174/138161210791293042
PII: BSP/CPD/E-Pub/00073
Knihovny.cz E-resources
- MeSH
- Biological Availability MeSH
- Phenols chemistry MeSH
- Pharmaceutical Preparations administration & dosage metabolism MeSH
- Drug Delivery Systems * MeSH
- Humans MeSH
- Neoplasms drug therapy physiopathology MeSH
- Prodrugs MeSH
- Antineoplastic Agents administration & dosage pharmacokinetics pharmacology MeSH
- Drug Design * MeSH
- Animals MeSH
- Check Tag
- Humans MeSH
- Animals MeSH
- Publication type
- Journal Article MeSH
- Research Support, Non-U.S. Gov't MeSH
- Review MeSH
- Names of Substances
- Phenols MeSH
- Pharmaceutical Preparations MeSH
- Prodrugs MeSH
- Antineoplastic Agents MeSH
Phenolic group in therapeutic drugs can be used for a prodrug modification to overcome various undesirable drug properties that may become pharmacological, pharmaceutical or pharmacokinetic barriers for application. Several strategies have been used in order to overcome the limited bioavailability of phenolic drugs. Classical design represents a nonspecific chemical approach to mask undesirable drug properties, limited bioavailability or chemical instability. Targeted prodrug design represents a new strategy for directed and efficient drug delivery. Particularly, targeting the prodrug to specific enzyme or specific membrane transporter has potential as selective drug delivery system mainly in cancer therapy. The article brings examples of ester, sulphate, carbamate, carbonate, phosphate and ether prodrugs as well as the limitations of these prodrug strategies. Some specific enzyme targets are also presented.
References provided by Crossref.org
